ステムセル研究所’s ASEAN Cell Banking Business Expansion
First written in FY2025-H1. 5 of 7 entries say "Advanced", first in FY2025. Latest entry: FY2026.
The whole theme swung hardest in 2026: 1 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As part of promoting overseas expansion, we established the local subsidiary "STEMCELL INNOVATIONS PTE. LTD." in Singapore in November 2024 and are making preparations to commence operations around the middle of the fiscal year ending March 2027.」
Following the establishment of the local subsidiary in Singapore, preparations are continuing to commence operations around the middle of the fiscal year ending March 2027. - FY2026-H1Recorded upfront investment for launching the Singapore businessAnnual report
「Selling, general and administrative expenses were also affected by upfront investment related to launching the Singapore business and higher advertising expenses, in addition to the corresponding increase in personnel costs. These expenses represent upfront investment with future business expansion in view, and profit margins are expected to improve as revenue scale expands.」
The Singapore business is at the stage of recording upfront investment related to its launch, described as expenditure made with future business expansion in view. - FY2025AdvancedAnnual report
「As the first step, we established a local subsidiary, "STEMCELL INNOVATIONS PTE. LTD.", in Singapore in November 2024 to enter the Southeast Asian (SEA) market, where economic growth is expected. We are currently making preparations to commence operations in the region during the fiscal year ending March 2026.」
Moving beyond the earlier preparation stage, the Company established a local subsidiary in Singapore in November 2024 and moved into preparations to commence operations during the fiscal year ending March 2026. - FY2025-H1First statedAnnual report
「The Company is currently focusing on expanding its business in Southeast Asia (ASEAN). The region has more than 10 million births annually, is expected to surpass Japan's GDP in 2027, and is projected to see significant growth in the cell banking market. As a first step, preparations are under way to establish a regional headquarters company (holding company) in Singapore, scheduled for completion by November. In the future, the Company aims to establish operating companies in Singapore and other ASEAN countries, including Vietnam and Indonesia, under the regional headquarters and develop new markets.」
For ステムセル研究所, ASEAN, with more than 10 million births annually, has been positioned as a new market. The Company has outlined for the first time preparations to establish a regional headquarters company in Singapore by November and plans to establish operating companies in individual countries in the future.